1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Celltrion Eyes Direct Global Sales To Bolster Margins, Growth

 
• By Jung Won Shin

Biosimilar specialist Celltrion is aiming for the next stage of growth by setting up its own global direct sales and marketing system and through a new subcutaneous formulation of infliximab, and is looking to begin discussions with existing overseas marketing partners.

Celltrion briefing
Celltrion Chairman Jung Jin Seo Speaks At A Briefing In Seoul • Source: Celltrion Inc.

Celltrion Group is seeking further growth and an improvement in profit margins through the setting up of its own direct global sales, marketing and distribution system for new products, and for its already commercialized lines if it is unable to find "win-win" strategies with existing partners for these.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Korean Biotech Roundup: GNT Set For First Direct Korean Biopharma IPO On Nasdaq

 
• By Jung Won Shin

GNT Pharma prepares for the first listing of a Korean biotech on Nasdaq, while others sign major global out-licensing deals with large multinational partners.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.

Compass’ Bispecific BTC Contender Meets Phase II/III Endpoint

 
• By Jung Won Shin

Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By Jung Won Shin

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.

More from Focus On Asia